FDAnews
www.fdanews.com/articles/122930-novo-nordisk-licenses-human-monoclonal-antibody-from-zymogenetics

Novo Nordisk Licenses Human Monoclonal Antibody From ZymoGenetics

December 11, 2009
Novo Nordisk and ZymoGenetics have signed an agreement where Novo Nordisk in-licenses a fully human anti-IL21 monoclonal antibody, or IL-21 mAb, developed by ZymoGenetics, as well as broad intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.
American Chronicle